Decision regret in men living with and beyond nonmetastatic prostate cancer in the United Kingdom: A population-based patient-reported outcome study.
LAPCD
cancer
decision regret
involvement in decision-making
oncology
patient-reported outcomes
prostate cancer
treatment decision-making
Journal
Psycho-oncology
ISSN: 1099-1611
Titre abrégé: Psychooncology
Pays: England
ID NLM: 9214524
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
28
11
2019
revised:
28
01
2020
accepted:
11
02
2020
pubmed:
18
2
2020
medline:
18
11
2020
entrez:
18
2
2020
Statut:
ppublish
Résumé
Clinical options for managing nonmetastatic prostate cancer (PCa) vary. Each option has side effects associated with it, leading to difficulty in decision-making. This study aimed to assess the relationship between patient involvement in treatment decision-making and subsequent decision regret (DR), and quantify the impact of health-related quality of life (HRQL) outcomes on DR. Men living in the United Kingdom, 18 to 42 months after diagnosis of PCa, were identified from cancer registration data and sent a questionnaire. Measures included the Decision Regret Scale (DRS), Expanded Prostate cancer Index Composite short form (EPIC-26), EQ-5D-5L, and an item on involvement in treatment decision-making. Multivariable ordinal regression was utilized, with DR categorized as none, mild, or moderate/severe regret. A total of 17 193 men with stage I-III PCa completed the DRS: 36.6% reported no regret, 43.3% mild regret, and 20.0% moderate/severe regret. The odds of reporting DR were greater if men indicated their views were not taken into account odds ratio ([OR] = 6.42, 95% CI: 5.39-7.64) or were involved "to some extent" in decision-making (OR = 4.63, 95% CI: 4.27-5.02), compared with men who were "definitely" involved. After adjustment, including for involvement, men reporting moderate/big problems with urinary, bowel, or sexual function were more likely to experience regret compared with men with no/small problems. Better HRQL scores were associated with lower levels of DR. This large-scale study demonstrates the benefit of patient involvement in treatment decision-making for nonmetastatic PCa. However, men experiencing side effects and poorer HRQL report greater DR. Promoting engagement in clinical decision-making represents good practice and may reduce the risk of subsequent regret.
Identifiants
pubmed: 32065691
doi: 10.1002/pon.5362
pmc: PMC7317932
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
886-893Subventions
Organisme : Prostate Cancer UK
ID : BO26/MO
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Psycho?Oncology published by John Wiley & Sons Ltd.
Références
BMJ Open. 2016 Dec 7;6(12):e013555
pubmed: 27927667
Patient Educ Couns. 2019 Apr;102(4):797-803
pubmed: 30527732
PLoS One. 2018 Feb 5;13(2):e0192097
pubmed: 29401514
BMC Fam Pract. 2016 Nov 10;17(1):156
pubmed: 27832752
J Clin Oncol. 2017 Jul 10;35(20):2306-2314
pubmed: 28493812
Cancer. 2008 Jan 1;112(1):61-8
pubmed: 18040996
Urology. 2008 Dec;72(6):1274-9
pubmed: 18313115
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Cancer Invest. 2007 Sep;25(6):449-57
pubmed: 17882657
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Psychooncology. 2020 May;29(5):886-893
pubmed: 32065691
Fam Pract. 2017 Feb;34(1):90-97
pubmed: 28034917
Med Decis Making. 2016 Aug;36(6):777-90
pubmed: 26975351
J Urol. 2014 Apr;191(4):964-70
pubmed: 24184370
BJU Int. 2007 Oct;100(4):780-5
pubmed: 17578466
Psychooncology. 2015 Sep;24(9):1002-11
pubmed: 25728586
BJU Int. 2012 May;109(10):1503-9
pubmed: 21883845
Expert Rev Pharmacoecon Outcomes Res. 2004 Apr;4(2):159-63
pubmed: 19807519
Lancet Oncol. 2019 Mar;20(3):436-447
pubmed: 30713036
Med Decis Making. 2003 Jul-Aug;23(4):281-92
pubmed: 12926578
Psychooncology. 2017 Nov;26(11):1825-1831
pubmed: 28124398
Lancet. 2003 Mar 22;361(9362):1045-53
pubmed: 12660074
Cancer. 2017 Nov 1;123(21):4252-4258
pubmed: 28678408